NCT06506955 2026-03-11
Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy.
Taiho Oncology, Inc.
Phase 2/3 Enrolling by invitation
Clinical Trials
5 trialsNCT04669496 2025-09-04
Phase II-III Clinical Trial of PD1 Antibody (Toripalimab), Lenvatinib and GEMOX Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors
Shanghai Zhongshan Hospital
Phase 2/3 Active not recruiting
NCT02807181 2025-05-09
SIRCCA
Sirtex Medical
Phase 2/3 Terminated
NCT06355427 2025-04-11
FAPIChol
Erasmus Medical Center
Phase 2/3 Recruiting
NCT06923475 2025-04-11
NEODISCO
Amsterdam UMC, location VUmc
Phase 2/3 Not yet recruiting